
Reset all filters
01 3Dolutegravir Products
02 3Dolutegravir products
03 11Dovato
04 2Epzicom/Kivexa
05 8Juluca
06 11Tivicay
07 15Triumeq
08 5Zeffix
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 2,117
2019 Revenue in Millions : 2,304
Growth (%) : -8
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 6,519
2019 Revenue in Millions : 6,423
Growth (%) : 1
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 3,197
2019 Revenue in Millions : 3,534
Growth (%) : -10
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 43
2019 Revenue in Millions : 104
Growth (%) : -59
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 518
2019 Revenue in Millions : 78
Growth (%) : 568
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 3,197
2019 Revenue in Millions : 3,534
Growth (%) : -10
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 686
2019 Revenue in Millions : 507
Growth (%) : 35
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 518
2019 Revenue in Millions : 78
Growth (%) : 568
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 2,547
2020 Revenue in Millions : 3,159
Growth (%) : -18
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 6,181
2020 Revenue in Millions : 6,442
Growth (%) : -3